4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001628280-23-016223
Chief Executive Officer sold 104,928 shares at an average $39.32 ($4,125,674)
- Chief Executive Officer acquired 104,928 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard Chief Executive Officer | 2023-05-03 | Option exercise | +54,928 | $2.01 | $110,405 | 3,816,266 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2023-05-03 | Sale | −54,928 | $39.14 | $2,149,882 | 3,761,338 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2023-05-04 | Option exercise | +50,000 | $2.01 | $100,500 | 3,811,338 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2023-05-04 | Sale | −24,008 | $38.97 | $935,592 | 3,787,330 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2023-05-04 | Sale | −25,992 | $40.02 | $1,040,200 | 3,761,338 | D |
| Derivatives | |||||||
| Anzalone Christopher Richard Chief Executive Officer | 2023-05-03 | Option exercise · Stock Option (right to buy) | −54,928 | 516,980 | D | ||
| Anzalone Christopher Richard Chief Executive Officer | 2023-05-04 | Option exercise · Stock Option (right to buy) | −50,000 | 466,980 | D | ||
| Open-market sales · 104,928 sh · avg $39.32 · $4,125,674 | |||||||
Loading xslF345X04/wf-form4_168332785863869.xml…